The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders

Drugs and Aging

Volumn 18, Issue 2, 2001, Pages 87-99

  Elliott, S ^a   Cawston, T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR;

DRUG SAFETY; DRUG USE; ENZYME INHIBITION; HUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

EID: 0035056510     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118020-00002     Document Type: Review

References (52)

1. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine
2. Proteoglycans: Many forms and many functions
3. The chondrocyte, architect of cartilage: Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules
4. In vivo studies of articular tissue damage mediated by catabolin/interleukin 1
5. In vivo studies of cartilage regeneration after damage induced by catabolin/interleukin-1
6. The capacity of pig articular cartilage in organ culture to regenerate after breakdown induced by complement-sufficient antiserum to pig erythrocytes
7. Collagen family of proteins
8. The breakdown of collagen by chondrocytes
9. Proteinases and inhibitors
10. Matrix metalloproteinases: A review
11. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family
12. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation
13. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen
14. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages
15. Binding of gelatinases A and B to type-I collagen and other matrix components
16. A matrix metalloproteinase expressed on the surface of invasive tumour cells
17. Activation of a recombinant membrane type l-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2
18. Furin-dependent intracellular activation of the human stromelysin-3 zymogen
19. The matrix-degrading metalloproteinases
20. Matrix metalloproteinase inhibitors in the treatment of arthritis
21. Collagenase: A key enzyme in collagen turnover
22. Characteristics of the action of human skin fibroblast collagenase on fibrillar collagen
23. The collagen substrate specificity of human neutrophil collagenase
24. Biochemical characterisation of human collagenase-3
25. Prevention of cartilage breakdown by matrix metalloproteinase inhibition: A realistic therapeutic target?
26. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis
27. Direct evidence for active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular cartilage
28. The degradation of type II collagen in rheumatoid arthritis: An immunoelectron microscopic study
29. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium
30. Joint destruction in arthritis: Metalloproteinases in the spotlight
31. Generation and characterization of aggrecanase - A soluble, cartilage-derived aggrecan-degrading activity
32. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family
33. An aggrecan-degrading activity associated with chondrocyte membranes
34. TNF-α converting enzyme (TACE) is inhibited by TIMP-3
35. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-a (cA2) therapy
36. 54 week clinical and radiographic results from the ATTRACT trial: A phase III study of infliximab (Remicade™) in patients with active RA despite methotrexate
37. Esculetin inhibits cartilage resorption induced by IL- 1 α in combination with OSM
38. Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts
39. Recent advances in matrix metalloproteinase inhibitor research
40. Matrix metalloproteinase inhibitors in arthritis
41. Wanted: The collagenase responsible for the destruction of the collage network in human cartilage
42. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
43. Mighty mice: Transgenic technology "knocks out" questions of metalloproteinase function
44. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
45. New collagenolytic enzymes cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: Destruction from above
46. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme
47. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis
48. Treatment of destructive arthritic disorders with MMP inhibitors: Potential role of tetracyclines
49. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation
50. Metalloproteinase inhibitors and the prevention of connective tissue breakdown
51. Inhibition of matrix metalloproteinases in rheumatoid arthritis
52. The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations